Bone marrow protection with trilaciclib and eribulin for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer that has spread or cannot be removed by surgery.
- You have already tried at least two previous chemotherapy treatments.
- Your cancer can be measured on scans.
- Your blood counts and organ function are within certain limits.
- You are able to take care of yourself (ECOG score 0 or 1).
- You have not had other cancers in the last 5 years, except for certain skin cancers.
- You have not had a stroke or heart problems in the last 6 months.
- You have not had a bone marrow or stem cell transplant.
- You are not allergic to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug that may help protect your bone marrow during chemotherapy, possibly reducing side effects like low blood counts. It is for people with certain advanced or recurrent solid tumors who are about to start a specific chemo regimen.
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.